Many Firsts As Celltrion/Pfizer's Inflectra Becomes Second US Biosimilar
This article was originally published in SRA
Executive Summary
Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb) has received approval from the US Food and Drug Administration as the first monoclonal antibody biosimilar licensed in the US1.
You may also be interested in...
Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors
Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.
Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors
Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.